<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836079</url>
  </required_header>
  <id_info>
    <org_study_id>101773-002</org_study_id>
    <nct_id>NCT03836079</nct_id>
  </id_info>
  <brief_title>SVC Occlusion in Subjects With Acute Decompensated Heart Failure</brief_title>
  <acronym>VENUS-HF</acronym>
  <official_title>Superior Vena Caval Occlusion in Subjects With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>preCARDIA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>preCARDIA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and performance evaluation of the preCARDIA System for patients with ADHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this early feasibility study is to evaluate the safety and performance of
      the preCARDIA System for Superior Vena Caval (SVC) intermittent mechanical occlusion as a
      therapeutic approach in significantly congested subjects with Acute Decompensated Heart
      Failure (ADHF), who are not diuresing adequately.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Major Adverse Events through 30 days.</measure>
    <time_frame>30 days</time_frame>
    <description>MAE is defined as death, myocardial infarction, major thromboembolic event, vascular damage requiring surgical intervention, hemorrhagic stroke or prolongation of heart failure- related hospitalization attributable to the preCARDIA device or procedure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>ADHF Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with preCARDIA System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>preCARDIA system</intervention_name>
    <description>Intermittent occlusion of the SVC</description>
    <arm_group_label>ADHF Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA Class III-IV heart failure

          -  Subjects with inadequate diuresis

          -  Stage C-D systolic heart failure

        Exclusion Criteria:

          -  Active myocardial ischemia or acute coronary syndrome (ACS)

          -  Severe aortic or mitral valve insufficiency

          -  Severe peripheral vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelsey Hedquist</last_name>
    <phone>651-252-1773</phone>
    <email>precardia@precardia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TUFTS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TUFTS Primary Site Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

